CARLY
Financiado
Development and characterization of a novel CAR T-cell therapy for NHL
Non-Hodgkin lymphomas (NHL) are a group of blood cancers characterized by the expansion of malignant B lymphocytes creating tumors throughout the body. The standard of care for patients with aggressive NHL is a combination of chem...
Non-Hodgkin lymphomas (NHL) are a group of blood cancers characterized by the expansion of malignant B lymphocytes creating tumors throughout the body. The standard of care for patients with aggressive NHL is a combination of chemotherapy and immunotherapy. Even though it is well tolerated, ~40% of the patients respond poorly and eventually relapse. Novel personalized treatment options are now available for such individuals and engage patients’ own T cells genetically manipulated to express a chimeric antigen receptor (CAR) capable to recognize and attack malignant cells. Thus far, CAR-T products recognizing and attacking cells expressing the protein CD19 have been approved by regulatory agencies across the planet. However, long-term follow-up studies show that more than half of these patients eventually succumb to relapse after CAR-T treatment. One of the causes for this is the loss of the CD19 protein on NHL cells. Therefore, finding other proteins beyond CD19 that could be targeted or co-targeted with CAR-T-cells is desired.
Indeed, in the proposed project, I intend to develop and characterize a CAR-T therapy directed against a cell surface protein highly expressed in NHL (preliminary data). Herein, I plan to evaluate the levels of the new target protein in a large cohort of NHL patients using immunohistochemistry and to perform a thorough preclinical assessment of this novel CAR-T-cell approach using cutting-edge preclinical NHL models. To achieve these goals, I will exploit the experience of the hosting institution in generating NHL patient-derived xenografts and in the bench-to-bedside CAR-T development process, as well as the external collaborators who are experts in blood cancer treatment.
This fellowship will significantly expose me to world-class theoretical and hands-on preclinical research in hematooncology and adoptive cell therapy, thus boosting my career as an independent researcher.
ver más
Duración del proyecto: 39 meses
Fecha Inicio: 2024-03-26
Fecha Fin: 2027-06-30
Fecha Fin: 2027-06-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-03-26
HORIZON EUROPE
No se conoce la línea exacta de financiación, pero conocemos el organismo encargado de la revisión del proyecto.
Líder del proyecto
FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEM...
No se ha especificado una descripción o un objeto social para esta compañía.
